10:31 ETGraves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsightprnewswire·1 day ago, 09:32 AMVRDN+0.10%
SEB Asset Management AB Makes New Investment in Viridian Therapeutics, Inc. $VRDNMarket Beat·Jul 24 at 03:58 AMVRDN+0.10%STT+3.85%
12:25 ETRaymond Douglas, MD, PhD, Is First in the Nation to Infuse Newly FDA-Approved Thyroid Eye Disease Treatment, LUMVOA ™ (veligrotug-vvze)prnewswire·Jul 16 at 11:26 AMVRDN+0.10%
Viridian Therapeutics (NASDAQ:VRDN) Lowered to Strong Sell Rating by Wall Street ZenMarket Beat·Jul 12 at 12:30 PMVRDN+0.10%STT+3.85%
Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA ApprovalSimplywall·Jul 10 at 04:18 PMVRDN+0.10%
Bombardier, Dividend 15, DRI Lead Scant Pack of Stocks at 52-Week HighsBaystreet·Jul 8 at 10:20 AMVRDN+0.10%
The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye DiseaseSimplywall·Jul 6 at 03:01 AMVRDN+0.10%
Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goalrttnews·Jul 2 at 09:15 AMNVS-0.25%VRTX-0.34%
Viridian Therapeutics (VRDN) Receives a Rating Update from a Top AnalystTip Ranks·Jun 30 at 09:05 PMVRDN+0.10%WFC+1.86%
Stock Futures Rise on Rebound in Tech Stocks, Easing Middle East TensionsTip Ranks·Jun 29 at 07:40 AM.SPX+1.66%.DJI+1.19%
VRDN: FDA approves Lumvoa for TED, offering rapid, durable relief and broad patient accessQuartr·Jun 29 at 09:52 AMVRDN+0.10%
Viridian Initiated at Buy as Lumivoa FDA Approval Transitions Company to Commercial Stage; $35 Price Target ReiteratedTip Ranks·Jun 29 at 09:15 AMVRDN+0.10%
